Skip to main content

Advertisement

Log in

Serum sulfatase activity is more elevated in colonic adenomas than cancers

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Background and aims

Elucidation of molecular basis of the adenomatous polyps (AP) and colorectal cancer (CRC) development is crucial for their prevention, early detection, and treatment. According to the recent discoveries, sulfatases are implied in extracellular matrix remodeling and degradation and also in the regulation of certain signaling pathways. However, their exact role in carcinogenesis remains unclear. Because the majority of CRCs arise from AP, the aim of our studies was the investigation of sulfatase activity in adenomas and adenocarcinomas and verification of possible usefulness of sulfatase activity determination as an indicator of the presence and discrimination between adenomas and carcinomas.

Patient–methods

One hundred twenty individuals were enrolled in the study. We assayed serum sulfatase activity in 79 patients with colorectal neoplasms (38 CRC and 41 AP) and 41 controls. Enzyme activity was determined colorimetrically.

Results

We found statistically higher serum sulfatase activity in patients with colonic neoplasms than in controls (124; 112–139 vs. 79.5; 73–87 U). The activity was more elevated in adenomas (149; 128–173 U) than in cancers (103; 90–112 U). Sulfatase activity exceeded the cutoff value in 71% of AP and 47% of CRC patients. It increased with number of adenomas and tended to decrease with tumor progression.

Conclusions

Sulfatases seem to be involved in the early stages of colonic neoplastic transformation which is reflected in their serum activity. The likelihood of elevated sulfatase activity is almost ten times higher in subjects with than without polyps. Sulfatase upregulation in majority of adenomas and their correlation tendencies warrants reconsideration of sulfatase determination as a possible diagnostic tool.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. WGO/OMGE Position Statement. (2004) Colorectal cancer screening and surveillance. World Gastroenterology News 9(Supplement 1–4)

    Google Scholar 

  2. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C, U.S. Multisociety Task Force on Colorectal Cancer (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. Gastroenterology 124:544–560

    Article  PubMed  Google Scholar 

  3. Diez-Roux G, Ballabio A (2005) Sulfatases and human disease. Annu Rev Genomics Hum Genet 6:355–379

    Article  PubMed  Google Scholar 

  4. Sanderson RD, Yang Y, Kelly T, MacLeod V, Dai Y, Theus A (2005) Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J Cell Biochem 96:897–905

    Article  PubMed  CAS  Google Scholar 

  5. Doucas H, Garcea G, Neal CP, Manson MM, Berry DP (2005) Changes in the Wnt signaling pathway in gastrointestinal cancers and their prognostic significance. Eur J Cancer 41:365–379

    Article  PubMed  CAS  Google Scholar 

  6. Katoh M (2005) WNT/PCP signaling pathway and human cancer (review). Oncol Rep 14:1583–1588

    PubMed  CAS  Google Scholar 

  7. Yi Y-F, Huang Y-R (1998) Arylsulfatase, b-galactosidase and lysozyme in gastric cancer cells and its relationship to invasion. World J Gastroenterol 4:52–54

    PubMed  Google Scholar 

  8. Liu D, Shriver Z, Venataraman G, Shabrawi YE, Sasisekharan R (2002) Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. PNAS 99:568–573

    Article  PubMed  CAS  Google Scholar 

  9. Wang S, Ai X, Freeman SD, Pownall ME, Lu Q, Kessler DS, Emerson CP (2004) Qsulf1, a heparan sulfate 6-0-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc Natl Acad Sci U S A 101:4833–4838

    Article  PubMed  CAS  Google Scholar 

  10. Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR, Shridhar V (2003) Loss of Hsulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 278:23107–23117

    Article  PubMed  CAS  Google Scholar 

  11. Green FL, Page DL, Fleming ID, Fritz A, Balch ChM, Haller DG, Morrow M (2002) AJCC Cancer Staging Manual, 6th edn. Springer, New York

    Google Scholar 

  12. Singh J, Tavella D, Di Ferrante N (1975) Measurements of arylsulfatases A and B in human serum. J Pediatr 86:574–576

    Article  PubMed  CAS  Google Scholar 

  13. Li J, Kleeff J, Abiatari I, Kayed H, Giese NA, Felix K, Giese T, Büchler MW, Friess H (2005) Enhanced levels of Hsulf-I interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer 4:14. DOI 10.1186/1476-4598-4-14

    Article  PubMed  Google Scholar 

  14. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD (2002) Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 277:49175–49185

    Article  PubMed  CAS  Google Scholar 

  15. Laidler P, Kowalski D, Silberring J (1991) Arylsulfatase A in serum from patients with cancer of various organ. Clin Chim Acta 204:69–78

    Article  PubMed  CAS  Google Scholar 

  16. Kocak H, Oner–Iyidogan Y, Kocak T, Oner P (2004) Determination of diagnostic and prognostic values of urinary interleukin-8, tumor necrosis factor-α, and leukocyte arylsulfatase-A activity in patients with bladder cancer. Clin Biochem 37:673–678

    Article  PubMed  CAS  Google Scholar 

  17. Woźniak A, Drewa T, Rozwodowska M, Drewa G, Lambrecht W, Wisniewska I (2002) Activity of some lysosomal enzymes in serum and in tumors of patients with squamous cell lung carcinoma. Neoplasma 49:10–15

    PubMed  Google Scholar 

  18. Turkmen S, Oner P, Cinarv F, Kocak H, Guvenen G, Altun H, Eryavuz Y (2001) Evaluation of leukocyte arylsulfatase-A activity in patients with breast cancer and benign breast disease. Cancer Lett 166:95–101

    Article  PubMed  CAS  Google Scholar 

  19. Morgan LR, Samuels MS, Thomas W, Krementz ET, Meeker W (1975) Arylsulfatase B in colorectal cancer. Cancer 36:2337–2345

    Article  PubMed  CAS  Google Scholar 

  20. Rozwodowska M, Drewa T, Wozniak A, Mila-Kierzenkowska C, Drewa L, Makarewicz R, Maciak R, Musialkiewicz D (2004) Changes in arylsulphatase activity in blood serum in patients with breast cancer before and after treatment. Pol Merkur Lekarski 17:252–254

    PubMed  Google Scholar 

  21. Wagenaar-Miller RA, Hanley G, Brandt-Shattuck R, DuBois RN, Bell RL, Matrisian LM, Morgan DW (2003) Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction. Br J Cancer 88:1445–52

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Malgorzata Matusiewicz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matusiewicz, M., Krzystek-Korpacka, M., Diakowska, D. et al. Serum sulfatase activity is more elevated in colonic adenomas than cancers. Int J Colorectal Dis 23, 383–387 (2008). https://doi.org/10.1007/s00384-007-0434-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-007-0434-4

Keywords

Navigation